CRVO CervoMed Inc.

$2.73

CervoMed Inc. (CRVO) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.53 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.9% since its last earnings release on August 7, 2026.

CervoMed Beat Consensus Estimates
Friday, August 7, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:30 AM ET
Earnings Whisper
-
vs ($0.53)
Rev est $300K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.93

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About CervoMed Inc.

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics for patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant which inhibits p38MAP kinase alpha. CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., is based in BOSTON.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow